View in EDS

Exceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 Expression.

Saved in:
Bibliographic Details
Title: Exceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 Expression.
Authors: Kong BL; Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Stommel JM; Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Keck JM; Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Kilburn D; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.; Division of Oncological Sciences Knight Cancer Institute, Oregon Health and Science University, Portland, OR., Streblow A; Oregon Health & Science University School of Medicine, Portland, OR., Egger J; Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Creason AL; Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Suciu CG; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.; Department of Diagnostic Radiology, Oregon Health & Science University, Portland, OR., Guimaraes AR; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.; Division of Oncological Sciences Knight Cancer Institute, Oregon Health and Science University, Portland, OR.; Department of Pathology, Oregon Health & Science University, Portland, OR., Corless CL; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.; Department of Diagnostic Radiology, Oregon Health & Science University, Portland, OR., Mills GB; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.; Division of Oncological Sciences Knight Cancer Institute, Oregon Health and Science University, Portland, OR., Pejovic TB; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
Source: JCO precision oncology [JCO Precis Oncol] 2024 Jun; Vol. 8, pp. e2300686.
Publication Type: Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-4284
DOI:10.1200/PO.23.00686